de Citadel Advisors Charles River Laboratories CRL Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 271 M | Vender |
1,193,601
-18,551
| -2% | -USD 3.3 M | 0.03% | 411 |
|
|
2026
Q1 | USD 209 M | Comprar |
1,212,152
+794,636
| +190% | +USD 147 M | 0.03% | 440 |
|
|
2025
Q4 | USD 83.3 M | Comprar |
417,516
+299,486
| +254% | +USD 54.3 M | 0.01% | 986 |
|
|
2025
Q3 | USD 18.5 M | Vender |
118,030
-446,561
| -79% | -USD 70.9 M | ﹤0.01% | 2439 |
|
|
2025
Q2 | USD 85.7 M | Comprar |
564,591
+282,574
| +100% | +USD 37.7 M | 0.01% | 863 |
|
|
2025
Q1 | USD 42.4 M | Comprar |
282,017
+111,391
| +65% | +USD 18.7 M | 0.01% | 1271 |
|
|
2024
Q4 | USD 31.5 M | Comprar |
170,626
+156,429
| +1,102% | +USD 30.1 M | 0.01% | 1701 |
|
|
2024
Q3 | USD 2.8 M | Vender |
14,197
-14,665
| -51% | -USD 3.05 M | ﹤0.01% | 4918 |
|
|
2024
Q2 | USD 5.96 M | Comprar |
28,862
+25,578
| +779% | +USD 5.8 M | ﹤0.01% | 3476 |
|
|
2024
Q1 | USD 890 k | Comprar |
3,284
+3,094
| +1,628% | +USD 739 k | ﹤0.01% | 7156 |
|
|
2023
Q4 | USD 44.9 k | Vender |
190
-6,280
| -97% | -USD 1.24 M | ﹤0.01% | 11895 |
|
|
2023
Q3 | USD 1.27 M | Vender |
6,470
-20,200
| -76% | -USD 4.15 M | ﹤0.01% | 6095 |
|
|
2023
Q2 | USD 5.61 M | Comprar |
26,670
+19,370
| +265% | +USD 3.85 M | ﹤0.01% | 3475 |
|
|
2023
Q1 | USD 1.47 M | Vender |
7,300
-33,332
| -82% | -USD 7.55 M | ﹤0.01% | 5947 |
|
|
2022
Q4 | USD 8.85 M | Comprar |
40,632
+22,298
| +122% | +USD 4.87 M | ﹤0.01% | 2996 |
|
|
2022
Q3 | USD 3.61 M | Comprar |
18,334
+2,543
| +16% | +USD 549 k | ﹤0.01% | 4442 |
|
|
2022
Q2 | USD 3.38 M | Vender |
15,791
-208,775
| -93% | -USD 51 M | ﹤0.01% | 4549 |
|
|
2022
Q1 | USD 63.8 M | Comprar |
224,566
+24,222
| +12% | +USD 7.47 M | 0.01% | 943 |
|
|
2021
Q4 | USD 75.5 M | Comprar |
200,344
+35,873
| +22% | +USD 13.9 M | 0.02% | 862 |
|
|
2021
Q3 | USD 67.9 M | Vender |
164,471
-105,336
| -39% | -USD 43.7 M | 0.01% | 903 |
|
|
2021
Q2 | USD 100 M | Comprar |
269,807
+185,911
| +222% | +USD 62.1 M | 0.02% | 673 |
|
|
2021
Q1 | USD 24.3 M | Vender |
83,896
-137,894
| -62% | -USD 38.3 M | 0.01% | 1738 |
|
|
2020
Q4 | USD 55.4 M | Comprar |
221,790
+171,542
| +341% | +USD 40.9 M | 0.01% | 878 |
|
|
2020
Q3 | USD 11.4 M | Vender |
50,248
-152,079
| -75% | -USD 31.6 M | ﹤0.01% | 2139 |
|
|
2020
Q2 | USD 35.3 M | Comprar |
202,327
+56,556
| +39% | +USD 9.03 M | 0.01% | 1031 |
|
|
2020
Q1 | USD 18.4 M | Comprar |
145,771
+32,398
| +29% | +USD 4.86 M | 0.01% | 1304 |
|
|
2019
Q4 | USD 17.3 M | Comprar |
+113,373
| Nuevas | +USD 15.7 M | 0.01% | 1622 |
|
|
2019
Q3 | – | Vender |
-211,827
| Cerradas | -USD 28.4 M | – | 9225 |
|
|
2019
Q2 | USD 30.1 M | Comprar |
211,827
+208,224
| +5,779% | +USD 28.2 M | 0.01% | 1074 |
|
|
2019
Q1 | USD 523 k | Vender |
3,603
-9,855
| -73% | -USD 1.29 M | ﹤0.01% | 6721 |
|
|
2018
Q4 | USD 1.52 M | Vender |
13,458
-16,684
| -55% | -USD 2.09 M | ﹤0.01% | 4600 |
|
|
2018
Q3 | USD 4.06 M | Comprar |
30,142
+25,892
| +609% | +USD 3.2 M | ﹤0.01% | 3270 |
|
|
2018
Q2 | USD 477 k | Comprar |
4,250
+2,255
| +113% | +USD 244 k | ﹤0.01% | 6447 |
|
|
2018
Q1 | USD 213 k | Vender |
1,995
-77,000
| -97% | -USD 8.3 M | ﹤0.01% | 7259 |
|
|
2017
Q4 | USD 8.65 M | Comprar |
78,995
+45,952
| +139% | +USD 5 M | 0.01% | 1875 |
|
|
2017
Q3 | USD 3.57 M | Vender |
33,043
-253,770
| -88% | -USD 26.1 M | ﹤0.01% | 2700 |
|
|
2017
Q2 | USD 29 M | Comprar |
286,813
+149,202
| +108% | +USD 13.7 M | 0.02% | 778 |
|
|
2017
Q1 | USD 12.4 M | Vender |
137,611
-24,728
| -15% | -USD 2.1 M | 0.01% | 1284 |
|
|
2016
Q4 | USD 12.4 M | Vender |
162,339
-33,060
| -17% | -USD 2.51 M | 0.01% | 1205 |
|
|
2016
Q3 | USD 16.3 M | Comprar |
195,399
+93,462
| +92% | +USD 7.83 M | 0.02% | 994 |
|
|
2016
Q2 | USD 8.4 M | Comprar |
101,937
+96,687
| +1,842% | +USD 7.96 M | 0.01% | 1381 |
|
|
2016
Q1 | USD 399 k | Vender |
5,250
-44,215
| -89% | -USD 3.27 M | ﹤0.01% | 4720 |
|
|
2015
Q4 | USD 3.98 M | Vender |
49,465
-6,090
| -11% | -USD 439 k | ﹤0.01% | 2024 |
|
|
2015
Q3 | USD 3.53 M | Vender |
55,555
-111,546
| -67% | -USD 8.01 M | ﹤0.01% | 2285 |
|
|
2015
Q2 | USD 11.8 M | Comprar |
167,101
+30,400
| +22% | +USD 2.25 M | 0.01% | 1363 |
|
|
2015
Q1 | USD 10.8 M | Comprar |
136,701
+123,373
| +926% | +USD 9.1 M | 0.01% | 1379 |
|
|
2014
Q4 | USD 848 k | Comprar |
13,328
+13,123
| +6,401% | +USD 823 k | ﹤0.01% | 3965 |
|
|
2014
Q3 | USD 12 k | Vender |
205
-157,043
| -100% | -USD 8.99 M | ﹤0.01% | 7692 |
|
|
2014
Q2 | USD 8.42 M | Comprar |
157,248
+120,260
| +325% | +USD 6.6 M | 0.01% | 1400 |
|
|
2014
Q1 | USD 2.23 M | Vender |
36,988
-1,197
| -3% | -USD 69.8 k | ﹤0.01% | 2535 |
|
|
2013
Q4 | USD 2.03 M | Comprar |
38,185
+20,733
| +119% | +USD 1.04 M | ﹤0.01% | 2540 |
|
|
2013
Q3 | USD 807 k | Vender |
17,452
-34,642
| -66% | -USD 1.59 M | ﹤0.01% | 3316 |
|
|
2013
Q2 | USD 2.14 M | Comprar |
+52,094
| Nuevas | +USD 2.23 M | ﹤0.01% | 2426 |
|
Otros fondos que tienen CRL en su cartera
Posición de Citadel Advisors en CRL: resumen de T2 2026
Citadel Advisors redujo su participación en Charles River Laboratories (CRL) en 1.5% durante T2 2026, al vender acciones por un valor estimado de USD 3.3 M, y conservó 1,193,601 acciones valuadas en USD 271 M. La posición representa 0.03% de la cartera y ocupa el puesto #411.
Citadel Advisors reportó por primera vez una posición en CRL en T2 2013 y la ha mantenido durante 52 trimestres desde entonces. Al cierre de T2 2026, 571 fondos que sigue Wall St. Rank mantienen una posición en CRL.
- Al cierre de T2 2026, Citadel Advisors tenía 1,193,601 acciones de Charles River Laboratories con un valor de USD 271 M.
- Citadel Advisors vendió 18,551 acciones de Charles River Laboratories en T2 2026, por un valor estimado de USD 3.3 M.
- Charles River Laboratories representó 0.03% de la cartera de Citadel Advisors en T2 2026 y fue su posición número 411.
- Citadel Advisors reportó por primera vez una posición en Charles River Laboratories en T2 2013 y la ha mantenido durante 52 trimestres desde entonces.
- Al cierre de T2 2026, 571 fondos que sigue Wall St. Rank tenían Charles River Laboratories en cartera.
Según el Informe 13F de Citadel Advisors correspondiente a T2 2026, presentado el 14 ago 2026.